Issue
Number 613
August 7, 2006
CONTENTS OF THIS ISSUE
- New: HAN issues official Health Advisory about a multi-state
investigation of potential rabies exposure at a summer camp
- ACIP publishes provisional recommendations for prevention of tetanus,
diphtheria, and pertussis among pregnant women
- ACIP updates provisional recommendations for prevention of varicella
- August is National Immunization Awareness Month
- MMWR publishes report on a pertussis outbreak in an Amish community
- FDA approves influenza vaccines to be manufactured for upcoming
influenza season
- New BRFSS estimates for influenza and pneumococcal vaccination
coverage among adults available from CDC
- National Influenza Vaccine Summit releases July newsletter
- Updated: IAC revises injection technique piece for providers
- IAC adds HPV and herpes zoster pages to its websites
- CDC releases guidelines for vaccinating kidney dialysis patients and
patients with chronic kidney disease
- New: 2006-07 inactivated influenza VIS available in audio and video
formats
----------------------------------------------------------
Back to Top
-----------------------------------------------------------
ABBREVIATIONS: AAFP, American Academy of Family Physicians; AAP, American
Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices;
CDC, Centers for Disease Control and Prevention; FDA, Food and Drug
Administration; IAC, Immunization Action Coalition; MMWR, Morbidity and
Mortality Weekly Report; NIP, National Immunization Program; VIS, Vaccine
Information Statement; VPD, vaccine-preventable disease; WHO, World Health
Organization.
-----------------------------------------------------------
(1 of 12)
August 7, 2006
NEW: HAN ISSUES OFFICIAL HEALTH ADVISORY ABOUT A MULTI-STATE INVESTIGATION
OF POTENTIAL RABIES EXPOSURE AT A SUMMER CAMP
On August 3, the Health Alert Network (HAN) issued an official CDC Health
Advisory concerning a multi-state investigation of potential rabies exposure
at a summer camp. The Health Advisory is reprinted below in its entirety.
**********************
THIS IS AN OFFICIAL CDC HEALTH ADVISORY
Distributed via Health Alert Network
August 3, 2006, 13:47 EDT (01:47 PM EDT)
MULTI-STATE INVESTIGATION OF POTENTIAL RABIES EXPOSURE AT A SUMMER CAMP
Since August 2, 2006, the Centers for Disease Control and Prevention (CDC)
has been collaborating with Group Workcamps Foundation, and state and local
health departments in 13 states, to investigate reports of the presence of
bats at a summer camp and assess the potential for exposures to rabies. The
camp lodging facility which is located in New Richmond, Ohio, hosted
approximately 440 teenagers and adults from 13 states (Florida, Illinois,
Indiana, Kansas, Kentucky, Michigan, Missouri, Ohio, Pennsylvania,
Tennessee, Virginia, West Virginia, and Wisconsin) from June 11-July 28.
This advisory provides information about the investigation, an update for
states that may receive inquiries due to public concerns about bats and
rabies, and criteria for conducting risk assessments to determine the need
for postexposure prophylaxis (PEP).
One or a few bats were observed to be present in the structure where the
campers slept on at least four different occasions. At the time of the first
observation on 2 July, two bats were present in the foyer of the building.
One bat escaped and one was killed and discarded by an adult. The following
week (9 July) another bat was seen in the sleeping area and it was similarly
killed and discarded. A few weeks later, on July 23, another bat was seen in
the sleeping area; it was also killed and discarded. On the night of the
fourth incident (25 or 26 July), a single bat was observed flying above the
sleeping area and then roosting on the ceiling 30-40 feet above the campers.
Adult chaperones monitored the situation to ensure the bat was not mobile,
before going to sleep. The Group Workcamps Foundation is working
collaboratively with local and state health departments and CDC to notify
the parents of each camper who attended the camp during the summer so that
any potential exposures to rabies will be identified and managed
appropriately. To date, no apparent direct contact with bats has been
reported by any camper and the actions being taken by the Group Workcamps
Foundation and the public health authorities are precautionary.
Similar potential rabies exposures occurred at a summer camp at Camp Potomac
Woods in Lucketts, Virginia. A follow-up evaluation found that the presence
of bats was common around the camp area, with additional bats found in
several sleeping shelters. Prompt action by the part of the Loudon County
Health Department and Virginia Department of Health identified 14 candidates
for PEP out of 950 total campers.
Human rabies PEP is recommended when potentially infectious material (e.g.
saliva) from a rabid animal or human is introduced via a bite, or comes into
direct contact with broken skin or mucous membranes. More detailed
information regarding evaluation for and administration of PEP is available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/00056176.htm
Additional information about rabies and its prevention is available from
your state health department and CDC, telephone 1-800-CDC-INFO
(1-800-232-4636) or at
http://www.cdc.gov/ncidod/dvrd/rabies
**********************
To access the Health Advisory online, go to:
http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00247
-----------------------------------------------------------
Back to Top
(2 of 12)
August 7, 2006
ACIP PUBLISHES PROVISIONAL RECOMMENDATIONS FOR PREVENTION OF TETANUS,
DIPHTHERIA, AND PERTUSSIS AMONG PREGNANT WOMEN
On August 1, ACIP posted "Prevention of Tetanus, Diphtheria and Pertussis
among Pregnant Women: Provisional ACIP Recommendations for the Use of Tdap
Vaccine." ACIP voted on these recommendations on June 30.
The provisional recommendations are reprinted below in their entirety.
***********************
Provisional Recommendations for use of Td and Tdap in Pregnant Women
(adolescents 11-18 years and adults 19-64 years of age) who previously have
not received Tdap
-
Routine post-partum Tdap: Pregnant women who previously have not received
a dose of Tdap (including women who are breastfeeding) should receive Tdap
after delivery, before discharge from the hospital or birthing center, if
2 years or more have elapsed since the last Td; shorter intervals can be
used (see Special Situations). If Tdap cannot be administered before
discharge, it should be given as soon as feasible. The dose of Tdap
replaces the next decennial dose of Td.
-
Simultaneous administration: Tdap can be administered with other vaccines
that are indicated. Each vaccine should be administered using a separate
syringe at a different anatomic site.
Special Situations
-
Post-partum Tdap when less than 2 years have elapsed since the last Td:
Healthcare providers should obtain a history of adverse reaction
following previous doses of vaccines containing tetanus and diphtheria
toxoids. Available information is limited on the risk of local and
systemic reactions after Tdap at interval shorter than 2 years.
Providers can choose to administer Tdap to these post-partum women for
protection against pertussis.
-
Protection against tetanus, diphtheria, and neonatal tetanus: ACIP
recommends Td for booster vaccination during pregnancy if 10 years or
more have elapsed since a previous Td booster. To provide protection
against pertussis in addition to tetanus and diphtheria, healthcare
providers can defer the Td vaccination until delivery if sufficient
tetanus protection is likely. Sufficient tetanus protection is likely
if:
-
The pregnant woman is younger than 30 years of age and has received a
complete childhood series of immunization (4 or 5 doses of pediatric
DTP, DTaP, DT)** and at least one Td booster during adolescence or as
an adult.
-
The pregnant woman is older than 30 years of age and has received a
complete childhood series of immunization (4 or 5 doses of pediatric
DTP, DTaP, DT)**, and at least two Td booster doses.
-
The pregnant woman has a protective level of serum tetanus antitoxin
(0.1 IU/mL or more by ELISA).
** A primary series consisting of 3 doses of Td (or TT) administered
during adolescence or as an adult substitutes for the childhood series
of immunization.
-
Considerations for use of Td and Tdap in pregnant women: ACIP
recommends Td when tetanus and diphtheria protection is required
during pregnancy. In some situations (see below), healthcare providers
can choose to administer Tdap instead of Td to add protection against
pertussis. When Td or Tdap is administered during pregnancy, the
second or third trimester is preferred. Pregnancy is not a
contraindication for use of Tdap. Data on safety, immunogenicity, and
the outcomes of pregnancy are not available for pregnant women who
receive Tdap. When Tdap is administered during pregnancy,
transplacental maternal antibodies might protect the infant against
pertussis in early life. They also could interfere with the infant's
immune response to infant doses of DTaP, and leave the infant less
well protected against pertussis.
-
Providers who choose to administer Tdap to pregnant women should
discuss the lack of data with the pregnant women and are encouraged
to report Tdap administrations regardless of the trimester, to the
appropriate manufacturers' pregnancy registry: for BOOSTRIX(R) to
GlaxoSmithKline Biologicals at 1-888-825-5249, or for ADACEL (R) to
sanofi pasteur at 1-800-822-2463 (1-800-VACCINE).
-
Situations with increased risk for pertussis: Healthcare
providers can choose to administer Tdap instead of Td to
protect against pertussis in pregnant adolescents for
routine or "catch-up" vaccination because the incidence of
pertussis is high among adolescents, in pregnant healthcare
personnel, and child care providers to prevent transmission
to infants younger than 12 months of age and to other
vulnerable persons, and in pregnant women employed in an
institution or living in a community with increased
pertussis activity.
-
Tetanus prophylaxis for wound protection: ACIP recommends
Td booster for wound management in pregnant women in some
situations if 5 or more years have elapsed since the
previous Td. Healthcare providers can choose to substitute
Tdap for Td in this situation.
-
Incomplete or unknown vaccination history: Pregnant women
who have not received three doses of a vaccine containing
tetanus and diphtheria toxoids should complete a series of
3 vaccinations. Two doses of Td should be administered
during pregnancy to ensure protection against maternal and
neonatal tetanus. The preferred schedule in pregnant women
is two doses of Td separated by 4 weeks, and a dose of Tdap
6 months after the second dose (post-partum). Healthcare
providers can choose to substitute a single dose of Tdap
for a dose of Td during pregnancy.
-
Alternatives to Tdap for protection against pertussis:
Healthcare providers should encourage vaccination of
household and child care provider contacts of infants
younger than 12 months to protect against pertussis.
Families can be advised of the symptoms of pertussis and
that early antimicrobial prophylaxis can be effective
preventing transmission of pertussis to infants.
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5503a1.htm
http://www.cdc.gov/nip/recs/provisional_recs/default.htm
Contraindications to Td and Tdap
-
History of serious allergic reaction (i.e., anaphylaxis) to
any component of the vaccine.
-
For Tdap (but not Td), history of encephalopathy (e.g.,
coma or prolonged seizures) not attributable to an
identifiable cause within 7 days of administration of a
vaccine with pertussis components.
Precautions and Reasons to Defer Td or Tdap
-
Guillain-Barré syndrome with onset 6 weeks or less after
the previous dose of tetanus toxoid-containing vaccine.
-
Moderate or severe acute illness
-
History of an Arthus reaction to tetanus toxoid and/or
diphtheria toxoid-containing vaccine less than 10 years
previously
-
For adults, unstable neurologic conditions (e.g.,
cerebrovascular events, acute encephalopathic conditions)
-
For adolescents, any progressive neurologic disorder
including progressive encephalopathy or uncontrolled
epilepsy (until the condition has stabilized)
To access these provisional recommendations online, go to:
http://www.cdc.gov/nip/recs/provisional_recs/tdap-preg.pdf
All provisional ACIP recommendations can be found at
http://www.cdc.gov/nip/recs/provisional_recs
All published ACIP recommendations can be accessed at
http://www.cdc.gov/nip/ACIP
-----------------------------------------------------------
Back to Top
(3 of 12)
August 7, 2006
ACIP UPDATES PROVISIONAL RECOMMENDATIONS FOR PREVENTION OF
VARICELLA
On August 3, ACIP updated its provisional recommendations for
prevention of varicella. The provisional recommendations were
first posted in November 2005.
The updated provisional recommendations are reprinted below in
their entirety.
***********************
In June 2005 and June 2006, the ACIP made policy changes for use
of live, attenuated varicella-containing vaccines for prevention
of varicella. Changes include routine two dose varicella
vaccination of children and second dose catch-up varicella
vaccination for children, adolescents, and adults who previously
had received only one dose. The ACIP also expanded
recommendations for varicella-containing vaccines to promote
wider use of the vaccine for adolescents, adults, and HIV-infected children and approved new criteria for evidence of
immunity to varicella.
Provisional recommendations for prevention of varicella:
-
All children <13 years of age should be administered
routinely two doses of varicella-containing vaccine, with
the first dose administered at 12-15 months of age and the
second dose at 4-6 years of age (i.e., before a child
enters kindergarten or first grade). The second dose can be
administered at an earlier age provided the interval
between the first and second dose is at least 3 months.
However, if the second dose is administered at least 28
days following the first dose, the second dose does not
need to be repeated.
-
A second dose catch-up varicella vaccination is recommended
for children, adolescents, and adults who previously had
received one dose, to improve individual protection against
varicella and for more rapid impact on school outbreaks.
Catch-up vaccination can be implemented during routine
healthcare provider visits and through school and college
entry requirements. Catch-up second dose can be
administered at any interval longer than 3 months after the
first dose.
Remark:
The two-dose varicella vaccination schedule is similar to the
measles, mumps, and rubella (MMR) vaccination schedule. Measles,
mumps, rubella, and varicella (MMRV) vaccine is licensed and
indicated for simultaneous vaccination against measles, mumps,
rubella, and varicella among children 12 months through 12 years
of age. For routine immunization, use of licensed combination
vaccines, such as MMRV vaccine, is preferred over separate
injection of equivalent component vaccines.
-
Middle, high school, and college requirements. ACIP
reiterates its previous recommendation that official health
agencies should take necessary steps, including developing
and enforcing school immunization requirements, to ensure
that students at all grade levels (including college) and
children in child care facilities are protected against
vaccine-preventable diseases, including varicella. For
varicella, this recommendation adds middle school, high
school, and college requirements to the child care and
elementary school entry requirements already covered by the
1999 recommendation
(http://www.cdc.gov/mmwr/PDF/rr/rr4806.pdf). School and
child care immunization requirements should be implemented
when provision of varicella vaccine has been well
incorporated into practice and supply is adequate.
-
Varicella vaccination of HIV-infected children. HIV-infected children >=12 months of age in CDC clinical class
N, A, or B with CD4+ T-lymphocyte counts >=15% and without
evidence of varicella immunity should receive two doses of
single antigen varicella vaccine at a minimum interval of 3
months. Varicella vaccine was recommended previously for
asymptomatic or mildly symptomatic HIV-infected children
(CDC clinical class N and A) with age-specific CD4+ T-lymphocyte counts >=25%
(http://www.cdc.gov/mmwr/PDF/rr/rr4806.pdf). Because data
are not available on safety, immunogenicity or efficacy of
MMRV vaccine in HIV-infected children, MMRV vaccine should
not be administered as a substitute for the component
vaccines when vaccinating HIV infected children.
-
Prenatal assessment and postpartum vaccination. Women
should be assessed prenatally for evidence of varicella
immunity. Upon completion or termination of their
pregnancies, women who do not have evidence of varicella
immunity should receive the first dose of varicella vaccine
before discharge from the healthcare facility. The second
dose should be administered 4 to 8 weeks later (at the
postpartum or other healthcare visit). To ensure
administration of varicella vaccine, standing orders are
recommended for healthcare settings where completion or
termination of pregnancy occurs.
-
Vaccination of people >=13 years of age. Varicella vaccine
was recommended previously for people >=13 years of age
without evidence of immunity who 1) have close contact with
people at high risk for severe disease (healthcare
providers and family contacts of immunocompromised people)
or 2) are at high risk for exposure or transmission
(http://www.cdc.gov/mmwr/preview/mmwrhtml/00042990.htm).
The ACIP now recommends that all other people >=13 years of
age without evidence of immunity be vaccinated with two
doses of varicella vaccine at an interval of 4-8 weeks. The
vaccine may be offered during routine healthcare visits.
-
Second dose varicella vaccine for outbreak control. During
a varicella outbreak, people who have received one dose of
varicella vaccine should receive a second dose, provided
the appropriate vaccination interval has elapsed since the
first dose (3 months for people 12 months to 12 years of
age and at least 4 weeks for people >=13 years of age).
Contraindications and precautions to use of varicella vaccine
are available at:
http://www.cdc.gov/mmwr/preview/mmwrhtml/00042990.htm
Revised criteria for evidence of immunity to varicella includes
any of the following:
-
Documentation of age-appropriate vaccination:
-
Preschool-aged children >=12 months of age: one dose
-
School-aged children, adolescents, and adults: two
doses(1)
-
Laboratory evidence of immunity(2) or laboratory confirmation
of disease
-
Born in the U.S. before 1980(3)
-
A healthcare provider diagnosis of varicella or healthcare
provider verification of history of varicella disease(4)
-
History of herpes zoster based on healthcare provider
diagnosis.
FOOTNOTES
-
For children who have received their first dose before age
13 years and the interval between the two doses was at least 28
days, the second dose is considered valid.
-
Commercial assays can be used to assess disease-induced
immunity, but they lack adequate sensitivity to detect reliably
vaccine-induced immunity (may yield false negative results).
-
For healthcare providers and pregnant women, birth before
1980 should not be considered evidence of immunity.
-
Verification of history or diagnosis of typical disease can
be done by any healthcare provider (e.g., school or occupational
clinic nurse, nurse practitioner, physician assistant,
physician). For people reporting a history of or presenting with
atypical and/or mild cases, assessment by a physician or their
designee is recommended and one of the following should be
sought: a) an epidemiologic link to a typical varicella case or
b) evidence of laboratory confirmation, if laboratory testing
was performed at the time of acute disease. When such
documentation is lacking, people should not be considered as
having a valid history of disease, because other diseases may
mimic mild atypical varicella.
***********************
To access the provisional varicella prevention recommendations
online, go to:
http://www.cdc.gov/nip/vaccine/varicella/varicella_acip_recs_prov_june_2006.pdf
All provisional ACIP recommendations can be found at
http://www.cdc.gov/nip/recs/provisional_recs
All published ACIP recommendations can be accessed at
http://www.cdc.gov/nip/ACIP
---------------------------------------------------------------
Back to Top
(4 of 12)
August 7, 2006
AUGUST IS NATIONAL IMMUNIZATION AWARENESS MONTH
August is recognized as National Immunization Awareness Month
(NIAM). The goal of NIAM is to increase awareness about
immunization across the life span. August is the perfect time to
encourage family, friends, coworkers, and patients to catch up
on their vaccinations as students get ready for school and
healthcare workers prepare for the upcoming influenza season.
Communities are encouraged to plan local health screenings or
fairs, media events, and other related immunization outreach
efforts during August to promote the benefits of immunization.
For more information and links to NIAM resources, go to CDC's
web page at http://www.cdc.gov/nip/events/niam
The following are some useful resources for educating parents
and patients on the value of vaccines.
Booklets
"Parents' Guide to Immunization" (CDC)
http://www.cdc.gov/nip/publications/Parents-Guide
"Plain Talk About Childhood Immunizations"
(Public Health-Seattle & King County, Washington)
http://www.metrokc.gov/health/immunization/childimmunity.htm
Videos
"Vaccines and Your Baby" (Vaccine Education Center)
http://www.vaccineinformation.org/video/chop2.asp
"Vaccines: Separating Fact from Fear" (Vaccine Education Center)
http://www.vaccineinformation.org/video/chop1.asp
Video clips related to vaccine-preventable diseases (IAC)
http://www.vaccineinformation.org/video/index.asp
Photos
Photos related to vaccine-preventable diseases (IAC)
http://www.vaccineinformation.org/photos
Brochures/handouts
"Immunizations for Babies. . . A Guide for Parents" (IAC)
http://www.immunize.org/catg.d/p4010imm.pdf
"When Do Children and Teens Need Vaccinations?" (IAC)
http://www.immunize.org/catg.d/when1.pdf
"Vaccinations for Adults. . . You're NEVER too old to get
immunized!" (IAC)
http://www.immunize.org/catg.d/p4030a.pdf
"Do I Need Any Vaccinations Today?" (IAC)
http://www.immunize.org/catg.d/4036need.pdf
"Questions parents ask about baby shots" (IAC)
http://www.immunize.org/catg.d/p4025.pdf
For more immunization educational tools for parents and
patients, visit the following web pages:
CDC: http://www.cdc.gov/nip/publications
IAC: http://www.immunize.org/free
Vaccine Education Center:
http://www.chop.edu/consumer/jsp/division/generic.jsp?id=75693
National Network for Immunization Information:
http://www.immunizationinfo.org/parents/index.cfm
American Academy of Pediatrics:
http://www.cispimmunize.org/fam/fam_main.html
--------------------------------------------------------------
Back to Top
(5 of 12)
August 7, 2006
MMWR PUBLISHES REPORT ON A PERTUSSIS OUTBREAK IN AN AMISH
COMMUNITY
CDC published "Pertussis Outbreak in an Amish Community—Kent
County, Delaware, September 2004–February 2005" in the August 4
issue of MMWR. Excerpts from the introduction and editorial
note, excluding references, are reprinted below.
***********************
Vaccine-preventable disease outbreaks continue to occur among
undervaccinated populations in the United States, including
contained religious communities. The Amish practice separation
from the world through group solidarity and caring for their
own. Amish religious doctrine does not prohibit vaccination;
however, coverage levels for routine childhood vaccination
remain low in many Amish communities. This report describes an
outbreak of pertussis in an Amish community in Kent County,
Delaware, during September 2004–February 2005, that resulted in
345 cases and affected primarily preschool-aged children. The
outbreak underscores the need to promote vaccination in Amish
communities through culturally appropriate strategies, such as
education and outreach to community leaders. . .
Outbreaks of vaccine-preventable diseases (VPDs), such as
rubella and Haemophilus influenzae type b, have been reported
in Amish communities. Control of VPDs in these communities
presents unique challenges, in part because of their isolation.
Amish persons typically have lower vaccination coverage and
often delay or avoid seeking medical care. Since 1980, public
health nurses in Delaware have conducted immunization clinics at
two fixed outreach sites in Amish homes, but coverage rates have
remained low. After the outbreak described in this report, DPH
staff distributed educational pamphlets discussing immunization
and VPDs, including information about Amish immunization
outreach clinics. The reasons cited by persons in Amish
households for failure to vaccinate children (e.g., fears of
vaccine-related adverse events and general lack of awareness
regarding vaccination) were not religious or doctrinal. This
suggests that enhanced outreach and education regarding
vaccination safety and protective benefits might help increase
coverage rates.
***********************
To access a web-text (HTML) version of the complete article, go
to: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5530a1.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to: http://www.cdc.gov/mmwr/PDF/wk/mm5530.pdf
To receive a FREE electronic subscription to MMWR (which
includes new ACIP statements), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html
---------------------------------------------------------------
Back to Top
(6 of 12)
August 7, 2006
FDA APPROVES INFLUENZA VACCINES TO BE MANUFACTURED FOR UPCOMING
INFLUENZA SEASON
On August 2, the Food and Drug Administration (FDA) announced
that it had approved this year's seasonal influenza vaccines
that include the new strains of virus judged likely to cause
influenza in the Northern Hemisphere in 2006–07.
This season's approved formulation for the U.S. vaccine is
identical to that recommended by both the World Health
Organization and FDA's Advisory Committee. The formulation
includes one strain that was used in last year's vaccine and two
new strains.
There are four vaccine manufacturers approved to market
influenza vaccines in the United States: Chiron Vaccines, Ltd;
GlaxoSmithKline Biologicals; MedImmune Vaccines, Inc.; and
Sanofi Pasteur. The manufacturers have projected making a total
of about 100 million doses of influenza vaccine for this season,
but these projections could change as manufacturing continues.
To read the complete FDA press release, go to:
http://www.fda.gov/bbs/topics/NEWS/2006/NEW01423.html
---------------------------------------------------------------
Back to Top
(7 of 12)
August 7, 2006
NEW BRFSS ESTIMATES FOR INFLUENZA AND PNEUMOCOCCAL VACCINATION
COVERAGE AMONG ADULTS AVAILABLE FROM CDC
New estimates are available for influenza and pneumococcal
vaccination coverage among adults age 65 years and older from
CDC's Behavioral Risk Factor Surveillance System (BRFSS).
To obtain the 2005 BRFSS estimates online, go to:
http://apps.nccd.cdc.gov/brfss Estimates can be obtained for
all states or by individual state. Choose "Immunization" as the
category.
---------------------------------------------------------------
Back to Top
(8 of 12)
August 7, 2006
NATIONAL INFLUENZA VACCINE SUMMIT RELEASES JULY NEWSLETTER
The National Influenza Vaccine Summit has posted its July 2006
newsletter online at http://www.ama-assn.org/ama1/pub/upload/mm/36/2006_summit_news_2.pdf
The National Influenza Vaccine Summit website is sponsored by
CDC and the American Medical Association. Besides the two issues
of its newsletter, the site includes presentations from meetings
and information about influenza vaccine manufacturing, supply,
and distribution.
To visit the National Influenza Vaccine Summit website, go to:
http://www.ama-assn.org/ama/pub/category/13732.html
---------------------------------------------------------------
Back to Top
(9 of 12)
August 7, 2006
UPDATED: IAC REVISES INJECTION TECHNIQUE PIECE FOR PROVIDERS
IAC recently revised its two-page piece on injection technique.
Changes include the addition of newly licensed vaccines, minor
revisions in language, and one change in recommended needle
size.
To access a ready-to-print (PDF) version of How to Administer
Intramuscular (IM) Injections and How to Administer Subcutaneous
(SC) Injections go to:
http://www.immunize.org/catg.d/p2020.pdf
---------------------------------------------------------------
Back to Top
(10 of 12)
August 7, 2006
IAC ADDS HPV AND HERPES ZOSTER PAGES TO ITS WEBSITES
Due to the licensure of human papillomavirus (HPV) and herpes
zoster (shingles) vaccines, IAC has added related informational
pages to its websites.
For HPV information for health professionals, go to:
http://www.immunize.org/HPV
For HPV information for the public, go to:
http://www.vaccineinformation.org/HPV
For herpes zoster information for health professionals, go to:
http://www.immunize.org/zoster
For herpes zoster information for the public, go to:
http://www.vaccineinformation.org/zoster
---------------------------------------------------------------
Back to Top
(11 of 12)
August 7, 2006
CDC RELEASES GUIDELINES FOR VACCINATING KIDNEY DIALYSIS PATIENTS
AND PATIENTS WITH CHRONIC KIDNEY DISEASE
CDC released a document titled "Guidelines for Vaccinating
Kidney Dialysis Patients and Patients with Chronic Kidney
Disease" in June 2006. The guidelines are summarized from
recommendations of the ACIP, and are available in PDF format at
http://www.cdc.gov/nip/publications/dialysis_guide.pdf
-------------------------------------------------------------
Back to Top
(12 of 12)
August 7, 2006
NEW: 2006-07 INACTIVATED INFLUENZA VIS AVAILABLE IN AUDIO AND
VIDEO FORMATS
The 2006-07 VIS for injectable trivalent inactivated influenza
vaccine (dated 6/30/06) is now available on IAC's website in
audio, multimedia, and web-page video formats. These formats are
intended for use with low-literacy, English-speaking patients.
The web-page video is specifically tailored to be able to work
for people who have slow Internet connections.
IAC is grateful to Healthy Roads Media for providing these
alternative versions. Healthy Roads Media offers health
information in a variety of formats and languages. For
information, go to: http://www.healthyroadsmedia.org
To access the audio version of the VIS, go to:
http://www.immunize.org/vis/#influenza In the
Inactivated Influenza Vaccine section, click on the link titled
"English 6/30/06 (audio VIS*)."
To access the multimedia or web-page video versions of the VIS,
go to: http://www.immunize.org/vis/#influenza In the Inactivated
Influenza Vaccine section, click on the link titled "English
6/30/06 (multimedia "movie" VIS*)." This will bring you to a
menu on the Healthy Roads Media website where you can chose
either the multimedia or web-page video format.
To access a ready-to-print (PDF) hard-copy version of the VIS,
go to: http://www.immunize.org/vis/2flu.pdf
For information about the use of VISs, and for VISs in a total
of 33 languages, visit IAC's VIS web section at
http://www.immunize.org/vis |
